AstraZeneca to present new research data at AHA 2017

AstraZeneca will be attending the upcoming American Heart Association (AHA) scientific sessions in Anaheim, California, where it will be sharing its latest cardiovascular, renal and metabolic disease research insights.

In association with its global biologics research and development arm MedImmune, the company will share 28 presentations, including two late-breaking trials, during the conference from November 11th to 15th.

These will include findings from the DACAB study assessing the use of Brilinta plus aspirin in patients who have received elective coronary artery bypass graft surgery, as well as a new analysis of the EXSCEL clinical trial of the drug Bydureon, the largest and most inclusive cardiovascular outcomes trial of any glucagon-like peptide-1 receptor agonist.

Additionally, early-stage data for potential new medicines will be shared in areas including cardiac regeneration, chronic kidney disease, acute coronary syndromes, and chronic heart failure.

Ludovic Helfgott, vice-president for cardiovascular and metabolic diseases, said: "With the breadth of our scientific updates at AHA 2017, we are at the forefront of the clinical debate, exploring the often unseen but vital connections between cardiovascular, renal and metabolic diseases."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.